CDK12 and neoplasm: Patients with CDK12 mutations often exhibit aggressive tumor phenotypes characterized by genomic instability and poor therapeutic outcomes, underscoring the kinase’s importance in maintaining genomic integrity and modulating cellular responses to treatment [21,22].